• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Alzheimer’s disease

ALZpath Secures Funding for Blood-Based Biomarker Testing for Alzheimer’s Disease Detection

by Fred Pennic 07/21/2023 Leave a Comment

ALZpath Secures Funding for Blood-Based Biomarker Testing for Alzheimer's Disease Detection

What You Should Know:  - ALZpath, a developer of blood-based diagnostic biomarker testing for Alzheimer's disease detection receives funding from the Alzheimer’s Drug Discovery Foundation (ADDF)’s Diagnostics Accelerator to accelerate the clinical availability  of ALZpathDx as a laboratory developed test (LDT).  - ALZpathDx is a novel, proprietary assay for blood-based measurement of phosphorylated tau at threonine 217 (pTau217), a highly accurate, diagnostic biomarker for
Read More

 Are Hospitals Ready for Alzheimer’s Treatment Approval?

by John Showalter, MD, Chief Product Officer at Linus Health 03/20/2023 Leave a Comment

 Are Hospitals Ready for Alzheimer's Treatment Approval?

The FDA’s recent accelerated approval of Leqembi was welcome news across the Alzheimer’s community. However, few health systems, medical practices, or providers are prepared for the extraordinary public interest in a treatment for Alzheimer’s disease – especially not one targeting mild cognitive impairment (MCI) and early dementia due to Alzheimer’s disease – that is likely headed their way soon. The unprecedented scale of the public health and marketing campaigns, the high prevalence of MCI in
Read More

Real-World Study Uses AI to Identify Undiagnosed Dementia in Primary Care

by Syed Hamza Sohail 12/28/2022 Leave a Comment

Real-World Study Uses AI to Identify Undiagnosed Dementia in Primary Care

What You Should Know: - Rising to meet the formidable challenge of the timely diagnosis of dementia, research scientists from Regenstrief Institute, IUPUI and the medical schools of Indiana University and the University of Miami are conducting the Digital Detection of Dementia study, a real-world evaluation of the use of an artificial intelligence (AI) tool they developed for early identification of Alzheimer’s disease and related dementias in primary care, the setting where most adults
Read More

Clinical Trials: 5 Steps to Greater eConsent Adoption

by Kate Godwin-Smith, Director, Client Services, Patient Consent Solutions, IQVIA Technologies 12/14/2022 Leave a Comment

Clinical Trials: 5 Steps to Greater eConsent Adoption

Clinical trials advance much-needed treatments while offering hope to patients and their families. However, the process of enrolling in a study where they will receive investigational medicines, vaccines or procedures can be a source of friction – enough for patients to rethink participation.  The weight of the decision combined with a perceived lack of transparency of information can confuse or dismay even those patients that are most savvy in the medical industry. Even if they do end
Read More

The Gains and Pains of Using AI in the Pharmaceutical Industry

by Michael Galarnyk, AI Evangelist at cnvrg.io 10/25/2022 Leave a Comment

The Gains and Pains of Using AI in the Pharmaceutical Industry

The costs for drug discovery and development are skyrocketing, but AI (artificial intelligence) is introducing new efficiencies to help find effective treatments faster. A study in 2020 concluded that the estimated median capitalized research and development cost per product was $985 million. Contributing factors to this included larger trial sizes, the need to assess health technology, the requirement to provide data on comparative drugs’ effectiveness, and most
Read More

Eyenuk Raises $26M for AI-Powered Eye Screening & Predictive Biomarkers

by Syed Hamza Sohail 10/17/2022 Leave a Comment

Eyenuk Raises $26M for AI-Powered Eye Screening & Predictive Biomarkers

What You Should Know: - Eyenuk, Inc., a global artificial intelligence (AI) digital health company and the leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, today announced it has secured $26 million in a Series A financing round, bringing the Company’s total funding to over $43 million. - The capital raise was led by AXA IM Alts and was joined by new and existing investors including T&W Medical A/S, A&C Foelsgaard Alternativer ApS, Kendall
Read More

Brain Health: The Next Frontier in the Fight Against Dementia

by Joyce Gomes-Osman, PT, PhD and Alvaro Pascual-Leone, MD, PhD at Linus Health 10/07/2022 Leave a Comment

Brain Health The Next Frontier in the Fight Against Dementia

There are differing views on the value of cognitive screening of older adults in a primary care setting. Many providers point to the lack of disease-modifying treatments for Alzheimer’s Dementia and related dementias (ADRD) as a reason to not universally screen older adults for cognitive deficits. If I don’t have anything to give my patients to get better, what’s the point in revealing they might be at risk of dementia, or that they have early disease? Is dementia a ‘normal’ or ‘expected’ part
Read More

Rippl Launches with $35M to Transform Mental Health for Seniors

by Fred Pennic 09/28/2022 Leave a Comment

Rippl Launches with $35M to Transform Mental Healthcare for Seniors

What You Should Know: - Rippl, a new mental health startup focused on caring for seniors with dementia and other neurocognitive conditions, launched today with $32M in seed round funding led by ARCH Venture Partners and General Catalyst. The round also includes investment from GV, F-Prime Capital, and Mass General Brigham Ventures. - Rippl will use its seed funding to hire and train a team of clinicians, build technology, and open a Washington state-based clinical support center to launch
Read More

Linus Health Launches AI Platform to Detect, Delay Dementia

by Syed Hamza Sohail 07/28/2022 Leave a Comment

Linus Health Launches AI Platform to Detect, Delay Dementia

What You Should Know: - Linus Health launches the first iPad-based cognitive screening platform able to detect cognitive decline such as dementia years before the human eye could ever do so. - Linus is now offering a solution to empower PCPs to not only pinpoint cognitive issues in just minutes but also leverage AI to provide patients with evidence-based early interventions IPad-Based Brain Health Platform Projections estimate that the number of people in the US with Alzheimer's
Read More

NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers

by Syed Hamza Sohail 07/28/2022 Leave a Comment

NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers

What You Should Know: - NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, and NeuraLight, a company developing objective and sensitive biomarkers for neurological disorders, today announced a collaboration to advance the science of digital biomarkers in the detection and monitoring of neurological diseases including amyotrophic lateral sclerosis (ALS). - This agreement marks NeuraLight’s first clinical trial and comes on the heels of
Read More

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |